Merck & Co Inc 8-k (events Or Changes Between Quarterly Reports) 2009-02-24
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Merck & Co Inc 8-k (events Or Changes Between Quarterly Reports) 2009-02-24 as PDF for free.
More details
- Words: 794
- Pages: 4
Processed and formatted by SEC Watch - Visit SECWatch.com
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
February 24, 2009
Merck & Co., Inc. __________________________________________ (Exact name of registrant as specified in its charter)
New Jersey _____________________ (State or other jurisdiction of incorporation)
1-3305 _____________ (Commission File Number)
One Merck Drive, P.O. Box 100, Whitehouse Station, New Jersey _________________________________ (Address of principal executive offices) Registrant’s telephone number, including area code:
22-1109110 ______________ (I.R.S. Employer Identification No.) 08889 ___________ (Zip Code) 908-423-1000
Not Applicable ______________________________________________ Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ [ [ [
] ] ] ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Processed and formatted by SEC Watch - Visit SECWatch.com
Top of the Form Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the "Company") on February 17, 2009, attached as Exhibit 99.1, announcing the election of Carlos E. Represas to the Company's Board of Directors, effective February 24, 2009. Board Committee assignments for Mr. Represas will be determined at a later date.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 Press Release issued February 17, 2009
Processed and formatted by SEC Watch - Visit SECWatch.com
Top of the Form SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc. February 24, 2009
By: /s/ Debra A. Bollwage Name: Debra A. Bollwage Title: Senior Assistant Secretary
Processed and formatted by SEC Watch - Visit SECWatch.com
Top of the Form Exhibit Index
Exh ibit No.
De scription
99.1
Press release issued February 17, 2009 Exhibit 99.1
News Release Media Contact:
Amy Rose (908) 423-6537
Investor Contact:
Eva Boratto (908) 423-5185
Carlos E. Represas Elected to Merck Board of Directors WHITEHOUSE STATION, N.J., Feb. 17, 2009 – Merck & Co., Inc. today announced that Carlos E. Represas, 63, chairman of Nestlé Mexico, will join the Company’s board of directors effective Feb. 24. With his election, Mr. Represas will become one of 13 outside directors on the 14member board. Mr. Represas will stand for election by the Company’s stockholders in April 2009. “Carlos has a broad range of global business experience that will be invaluable to Merck,” said Richard T. Clark, chairman, president, and chief executive officer. “We look forward to his insights and perspectives, and we welcome him to the board.” In 2004, Mr. Represas retired as executive vice president and head of the Americas for Nestlé S.A. Prior to serving in that role, he held positions of increasing responsibility during his 36 years at the company, including the position of chairman, president and CEO of Nestle Group Mexico from 1983 to 1994. Mr. Represas is a member of the Latin American Business Council and the boards of the Mexican Health Foundation and the Latin American Chamber of Commerce in Switzerland. Additionally, he is the chairman of the Board of Trustees of Mexico’s National Institute of Genomic Medicine. He also serves on the corporate board of Bombardier Inc., Canada. Mr. Represas earned a bachelor’s degree in economics from the National University of Mexico. He has been decorated by different South American countries and received Doctor Honoris Causa degrees from the Federal University of Vicosa in Brazil in 1998 and from the Mexican Academy of International Law in 2001. Separately, Merck announced last week that Dr. Johnnetta B. Cole resigned from the Board of Directors, effective March 1, to become Director of the Smithsonian’s National Museum of African Art. About Merck Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com. ###
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
February 24, 2009
Merck & Co., Inc. __________________________________________ (Exact name of registrant as specified in its charter)
New Jersey _____________________ (State or other jurisdiction of incorporation)
1-3305 _____________ (Commission File Number)
One Merck Drive, P.O. Box 100, Whitehouse Station, New Jersey _________________________________ (Address of principal executive offices) Registrant’s telephone number, including area code:
22-1109110 ______________ (I.R.S. Employer Identification No.) 08889 ___________ (Zip Code) 908-423-1000
Not Applicable ______________________________________________ Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: [ [ [ [
] ] ] ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Processed and formatted by SEC Watch - Visit SECWatch.com
Top of the Form Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Incorporated by reference is a press release issued by Merck & Co., Inc. (the "Company") on February 17, 2009, attached as Exhibit 99.1, announcing the election of Carlos E. Represas to the Company's Board of Directors, effective February 24, 2009. Board Committee assignments for Mr. Represas will be determined at a later date.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 Press Release issued February 17, 2009
Processed and formatted by SEC Watch - Visit SECWatch.com
Top of the Form SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Merck & Co., Inc. February 24, 2009
By: /s/ Debra A. Bollwage Name: Debra A. Bollwage Title: Senior Assistant Secretary
Processed and formatted by SEC Watch - Visit SECWatch.com
Top of the Form Exhibit Index
Exh ibit No.
De scription
99.1
Press release issued February 17, 2009 Exhibit 99.1
News Release Media Contact:
Amy Rose (908) 423-6537
Investor Contact:
Eva Boratto (908) 423-5185
Carlos E. Represas Elected to Merck Board of Directors WHITEHOUSE STATION, N.J., Feb. 17, 2009 – Merck & Co., Inc. today announced that Carlos E. Represas, 63, chairman of Nestlé Mexico, will join the Company’s board of directors effective Feb. 24. With his election, Mr. Represas will become one of 13 outside directors on the 14member board. Mr. Represas will stand for election by the Company’s stockholders in April 2009. “Carlos has a broad range of global business experience that will be invaluable to Merck,” said Richard T. Clark, chairman, president, and chief executive officer. “We look forward to his insights and perspectives, and we welcome him to the board.” In 2004, Mr. Represas retired as executive vice president and head of the Americas for Nestlé S.A. Prior to serving in that role, he held positions of increasing responsibility during his 36 years at the company, including the position of chairman, president and CEO of Nestle Group Mexico from 1983 to 1994. Mr. Represas is a member of the Latin American Business Council and the boards of the Mexican Health Foundation and the Latin American Chamber of Commerce in Switzerland. Additionally, he is the chairman of the Board of Trustees of Mexico’s National Institute of Genomic Medicine. He also serves on the corporate board of Bombardier Inc., Canada. Mr. Represas earned a bachelor’s degree in economics from the National University of Mexico. He has been decorated by different South American countries and received Doctor Honoris Causa degrees from the Federal University of Vicosa in Brazil in 1998 and from the Mexican Academy of International Law in 2001. Separately, Merck announced last week that Dr. Johnnetta B. Cole resigned from the Board of Directors, effective March 1, to become Director of the Smithsonian’s National Museum of African Art. About Merck Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com. ###
